Unicycive Therapeutics, an early-stage biotech developing in-licensed therapies for kidney disease, filed on Friday with the SEC to raise up to $36 million in an initial public offering.
Unicycive Therapeutics is primarily focused on developing therapies for kidney diseases. Its candidates include Renazorb, which was in-licensed from Spectrum Pharmaceuticals who conducted a Phase 1 trial for hyperphosphatemia in patients with chronic kidney disease in 2012, and UNI 494, which was in-licensed from Sphaera Pharmaceuticals. Unicycive began conducting preclinical trails on UNI 494 in 2020.
The Los Altos, CA-based company was founded in 2016 and plans to list on the Nasdaq under the symbol UNCY. Roth Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
